Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (343)	6/16/1998 7:37:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1494

NTII for a buck a share! Given the Merz deal has taken a lot of the risk out of NTII, that the company has two drugs in Phase II trials, and it has an exceptional, effective and connected CEO, this is a compelling share price. At a market cap for NTII of $6.5 million, IMHO this is a bargain. Compare this to a company like NEOT, that has one drug just entering phase II trials and little else, has a market cap ten times higher at $76 million. I bought more NTII today. John de C